Aarti Drugs: Moving up the pharma value chain

# Aarti Drugs: Moving up the pharma value chain Aarti Drugs Limited is moving beyond its traditional API business through backward integration, formulations and CDMO opportunities. The company plans ₹150–200 crore of annual capex for the next two years. The key focus is metformin. Aarti Drugs has already increased capacity to around 1,450–1,500 tonnes per month and plans to take this to 1,800–1,900 tonnes. It is also pursuing US FDA approval and plans to forward-integrate into metformin formulations. The company is also exploring CDMO opportunities in chlorosulfonation chemistry, where it already has manufacturing expertise, while expanding cardiovascular and antifungal products. This matters because APIs are more exposed to pricing cycles. Moving further downstream into regulated formulations and specialised manufacturing can potentially improve realisations and margins. Aarti Drugs has already completed around ₹600 crore of capex across Sayakha and Tarapur, while management estimates more than ₹1,200 crore of revenue potential from completed projects. **My view:** The interesting part of Aarti Drugs is the transition from an API-led business toward a more integrated pharma platform. The key test is whether the new capacity gets utilised fast enough to generate attractive returns on the capital invested. **What I'm watching:** Sayakha utilisation, metformin forward integration, regulated-market approvals, CDMO wins and return on capital. **Stance:** Capacity creation is only the first step. Execution and utilisation will determine whether the investment cycle translates into sustainable earnings growth. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.